Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guides
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Shares
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Advanced Medical Solutions reports solid end to 2024
(Sharecast News) - Tissue-healing technology specialist Advanced Medical Solutions Group reported robust growth for the year ended 31 December in an update on Tuesday, driven by strategic acquisitions and continued strength across its product portfolio. The AIM-traded company said it anticipated full-year revenue of £177m, up 40% from £126.2m in 2023.
EBITDA was expected to rise to between £40m to £40.5m, compared to £29.7m in the prior year, with adjusted pre-tax profit forecast at £29.2m to £29.7m, up from £25.9m.
The group said it completed two major acquisitions in 2024 - Syntacoll on 1 March and Peters Surgical on 1 July .
It said the integration of the businesses had progressed well, contributing significantly to its performance and enhancing its presence in the surgical product market.
Strong growth was seen across all surgical product categories, further solidifying the group's leadership in the sector.
In its wound care division, AMS said it had implemented strategic initiatives to adapt to shifting market dynamics.
The measures were expected to improve margins in 2025, positioning the business for continued profitability.
"The progress we made in the second half of 2024 has strengthened the confidence we have in the strategic rationale for the recent acquisitions of Peters Surgical and Syntacoll," said chief executive officer Chris Meredith.
"The synergistic benefits they represent to AMS, in terms of products, expertise, geographic reach and scale, are clearer than ever.
"As we start the new year as an enlarged and more competitive group, I remain confident and excited about the growth and opportunities that we expect in 2025 and beyond."
AMS said it would announce its full-year results on 19 March.
At 1322 GMT, shares in Advanced Medical Solutions Group were up 11.78% at 213.05p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Diversity, Equity & Inclusion Reports | Doing Business with Fidelity | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing programme
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.